
Lilly to Present New Verzenio Data and Pipeline Updates at ESMO 2025 Annual Meeting
Data includes seven-year results from monarchE trial and updates on multiple investigational cancer therapies. Eli Lilly and Company (NYSE: LLY) announced today that it will present new data from a…

Innate Pharma Schedules Analyst and Investor Event Focused on Lacutamab for October 28, 2025
Innate Pharma to Host Analyst and Investor Event Highlighting Lacutamab Clinical Data and Market Potential on October 28, 2025 Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA), a clinical-stage biopharmaceutical…

Oticara Reports Positive Phase 2 Results for Steroid Nasal Cream in Post-Surgical CRS
Oticara Reports Positive Phase 2 Results for Novel Nasal-Mucosa-Optimized Steroid Cream in Hard-to-Treat Post-Surgical Chronic Rhinosinusitis Oticara, a clinical-stage biopharmaceutical company focused on developing innovative therapies for chronic rhinosinusitis (CRS),…

BeOne Medicines Secures FDA Breakthrough Therapy Designation for Sonrotoclax
BeOne Medicines Earns FDA Breakthrough Therapy Designation for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma, Strengthening Its Global Oncology Leadership BeOne Medicines Ltd., a leading global oncology-focused biopharmaceutical company,…

Zai Lab to Present Updated Phase 1 Data on DLL3-Targeted ADC ZL-1310 at 2025 AACR-NCI-EORTC Conference
Zai Lab to Present Updated Phase 1 Data on DLL3-Targeted ADC Zocilurtatug Pelitecan (ZL-1310) at the 2025 AACR-NCI-EORTC International Conference Zai Lab Limited announced that new data from its global…

IDT and Hamilton Partner to Automate NGS and Boost Biomarker Discovery
IDT and Hamilton Partner to Automate NGS Workflows, Accelerating Biomarker and Genomic Discovery Integrated DNA Technologies (IDT), a global leader in genomics solutions, has announced a new strategic partnership with…

WuXi Biologics Earns MSCI AAA ESG Rating for Third Straight Year
WuXi Biologics Secures MSCI AAA ESG Rating for Third Consecutive Year, Reinforcing Global Sustainability Leadership WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), has announced…

AskBio Shares Interim Safety Data for AB-1003 in LGMD 2I/R9 Trial
AskBio Reports Interim Safety Data from Phase 1/2 LION-CS101 Trial of AB-1003 in Limb-Girdle Muscular Dystrophy 2I/R9 AskBio Inc. (AskBio), a gene therapy company wholly owned by Bayer AG and…

Zoetis Gets CVMP Green Light for Lenivia® to Relieve Canine Osteoarthritis Pain
Zoetis Receives Positive CVMP Opinion for Lenivia®, a Novel Therapy to Reduce Osteoarthritis Pain in Dogs Zoetis Inc., a global leader in animal health, today announced that the Committee for…

Satellos Reports Positive Safety and Functional Data for SAT-3247 in DMD First-in-Human Study
Satellos Bioscience Reports Promising Safety, Tolerability, and Functional Benefits of SAT-3247 in Adults with Duchenne Muscular Dystrophy Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF), a clinical-stage biotechnology company focused on…

Pulse Biosciences Presents Late-Breaking nPulse™ Cardiac System Data at EACTS 2025
Pulse Biosciences Unveils Promising First-in-Human Feasibility Data for the nPulse™ Cardiac Surgical System at EACTS 2025 Pulse Biosciences, Inc. (Nasdaq: PLSE), a clinical-stage medical technology company pioneering the use of…

Prilenia and Ferrer to Present New Pridopidine Data in Huntington’s Disease at HSG Congress
Prilenia and Ferrer Highlight Compelling New Evidence of Pridopidine’s Disease-Modifying Potential in Huntington’s Disease at the 2025 HSG Congress Prilenia Therapeutics B.V. and Ferrer have jointly announced the presentation of…

